ClinicalTrials.gg
CompletedNCT00117143Updated Jun 26, 2023Results posted

Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)

A Phase 1/2 interventional study of Romiplostim in Thrombocytopenic Purpura, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-26.

Primary conditionPurpura, Thrombocytopenic, IdiopathicRegistry: Purpura, ThrombocytopenicReclassifiedWhy we changed it
Registry
Purpura, Thrombocytopenic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Purpura, Thrombocytopenic, Idiopathic
Why
  1. The study's title name Purpura, Thrombocytopenic, Idiopathic, a narrower term within Purpura, Thrombocytopenic.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 6 months after the study started (first participant enrolled Dec 2002, registered Jun 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 6 under way, 2 of them phase 3. romiplostim · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
25th of 29
16 · median 62
Started
2002
with 1 other
Phase 1/2
3 of 29
none open now
Registered
4th of 29
by date
Lead sponsor
14 of 29
Amgen

Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, this one is the 25th largest by enrollment, is one of 2 that started in 2002, is one of 3 in phase 1/2, and was the 4th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

5 of the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About romiplostim

romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and tolerability of AMG 531 (romiplostim), a novel thrombopoiesis-stimulating peptibody, and its effect on platelet counts in adults with immune thrombocytopenic purpura.

03

Conditions studied

  • Thrombocytopenic Purpura

Browse trials for

Keywords

  • Immune Thrombocytopenic Purpura
  • Idiopathic Thrombocytopenic Purpura
  • ITP
  • Thrombocytopenia
04

In context

Purpura, Thrombocytopenic, Idiopathic Reclassified

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

This study's enrollment of 16 is below the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Purpura, Thrombocytopenic, Idiopathic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Purpura, Thrombocytopenic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Greater than or equal to 3 months history of ITP, regardless of splenectomy status, and completion of at least 1 prior treatment for ITP
  • 2 of 3 pretreatment counts that were less than 30 x 10\^9/L (if not currently on ITP therapy) or less than 50 x 10\^9/L (if currently receiving for ITP therapy)
  • Ability to give

Exclusion criteria

Exclusion Criteria:

  • Known history of arterial thrombosis, active , or bone marrow stem cell disorder
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Romiplostim

    Participants will receive a maximum of 2 administrations of romiplostim by subcutaneous injection, the first on day 1 of the study and the second on day 15 or 22 depending on the participant's platelet count. Romiplostim doses to be tested were 30, 100, 300, and 500 μg.

    Drug: Romiplostim

Interventions

  • Administered subcutaneously on day 1 and on day 15 or 22 if the platelet count was ≤ 50 x 10⁹/L and not rising, peak platelet count was ≤ 450 x 10⁹/L and no serious adverse events related to treatment were observed.

    Also known as: AMG 531, NPLATE

07

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    Time frame: From first dose through 8 weeks after last dose of study drug (11 weeks)

  2. Number of Participants With Positive Anti-Romiplostim Antibodies

    The presence or development of antibodies to romiplostim and endogenous thrombopoietin was assessed using a neutralizing bioassay. Antibody analyses were conducted on study days 29 and at the end-of-study visit (day 78). The number of participants with positive antibody binding at any time during the study is reported.

    Time frame: Days 29 and 78

Secondary outcomes

  1. Number of Participants Who Achieved a Targeted Therapeutic Platelet Response

    Targeted therapeutic platelet response was defined as a (single) platelet count that was double the baseline level and between 50 and 450 × 10⁹ cells/L. Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.

    Time frame: Baseline and after first dose (days 3, 5, 8, 10, 12, 15, and days 17 and 19 for participants dosed on day 22) and after second dose (days 17, 19, and 22 for participants dosed on day 15, and days 24, 26, 29, 32, 36, 43, 50, 64, and 78 in all participants)

  2. Number of Participants With an Increase in Platelet Count of ≥ 20 x 10⁹ Cells/L From Baseline

    Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.

    Time frame: Baseline and after first dose (days 3, 5, 8, 10, 12, 15, and days 17 and 19 for participants dosed on day 22) and after second dose (days 17, 19, and 22 for participants dosed on day 15, and days 24, 26, 29, 32, 36, 43, 50, 64, and 78 in all participants)

  3. Number of Participants With Peak Platelet Counts of ≥ 100 x 10⁹ Cells/L

    Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.

    Time frame: After first dose (days 3, 5, 8, 10, 12, 15, and days 17 and 19 for participants dosed on day 22), and after second dose (days 17, 19, and 22 for participants dosed on day 15, and days 24, 26, 29, 32, 36, 43, 50, 64, and 78 for all participants)

  4. Number of Participants With Peak Platelet Counts of ≥ 450 x 10⁹ Cells/L

    Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.

    Time frame: After first dose (days 3, 5, 8, 10, 12, 15, and days 17 and 19 for participants dosed on day 22), and after second dose (days 17, 19, and 22 for participants dosed on day 15, and days 24, 26, 29, 32, 36, 43, 50, 64, and 78 for all participants)

  5. Change From Baseline to Peak Platelet Level

    Platelet count data after the use of rescue medication were not included.

    Time frame: Baseline and after first dose (days 3, 5, 8, 10, 12, 15, and days 17 and 19 for participants dosed on day 22) and after second dose (days 17, 19, and 22 for participants dosed on day 15, and days 24, 26, 29, 32, 36, 43, 50, 64, and 78 in all participants)

  6. Time to Peak Platelet Count

    Time from the date of study drug administration (day 1, 15 or 22) to the day of peak platelet count after each dose. Platelet count data after the use of rescue medication were not included.

    Time frame: From first dose of study drug to day 15 or 22, and from the second dose of study drug (day 15 or 22) to day 78

  7. Duration Within the Targeted Therapeutic Range

    Targeted therapeutic platelet level was defined as a platelet count that was double the baseline level and between 50 and 450 × 10⁹ cells/L. Platelet count data after the use of rescue medication were not included.

    Time frame: From first dose of study drug to day 15 or 22, and from the second dose of study drug (day 15 or 22) to day 78

08

Results

Posted Dec 20, 2019

Participant flow

This was a multicenter study conducted in 6 centers in France, the Netherlands, and the United Kingdom.

Participant flow — Overall Study
MilestoneRomiplostim 30 µgRomiplostim 100 µgRomiplostim 300 µgRomiplostim 500 µg
Started4471
Received first dose4471
Received second dose4460
Completed4471
Not completed0000

Outcome measures

PrimaryNumber of Participants With Adverse Events
Time frame:
From first dose through 8 weeks after last dose of study drug (11 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsRomiplostim 30 µgRomiplostim 100 µgRomiplostim 300 µgRomiplostim 500 µg
All adverse events4471
Serious adverse events0031
Treatment-related adverse events1331
Serious treatment-related adverse events0011
Discontinuations due to adverse events0000
Deaths0000
PrimaryNumber of Participants With Positive Anti-Romiplostim Antibodies

The presence or development of antibodies to romiplostim and endogenous thrombopoietin was assessed using a neutralizing bioassay. Antibody analyses were conducted on study days 29 and at the end-of-study visit (day 78). The number of participants with positive antibody binding at any time during the study is reported.

Time frame:
Days 29 and 78
Reported as:
Count of participants · Participants
Number of Participants With Positive Anti-Romiplostim Antibodies
ParticipantsRomiplostim 30 µgRomiplostim 100 µgRomiplostim 300 µgRomiplostim 500 µg
Anti-romiplostim antibodies0000
Anti-thrombopoietin antibodies0000
SecondaryNumber of Participants Who Achieved a Targeted Therapeutic Platelet Response

Targeted therapeutic platelet response was defined as a (single) platelet count that was double the baseline level and between 50 and 450 × 10⁹ cells/L. Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.

Time frame:
Baseline and after first dose (days 3, 5, 8, 10, 12, 15, and days 17 and 19 for participants dosed on day 22) and after second dose (days 17, 19, and 22 for participants dosed on day 15, and days 24, 26, 29, 32, 36, 43, 50, 64, and 78 in all participants)
Reported as:
Count of participants · Participants
Number of Participants Who Achieved a Targeted Therapeutic Platelet Response
ParticipantsRomiplostim 30 µgRomiplostim 100 µgRomiplostim 300 µgRomiplostim 500 µg
After First Dose1440
After Second Dose133—
After Both Doses133—
SecondaryNumber of Participants With an Increase in Platelet Count of ≥ 20 x 10⁹ Cells/L From Baseline

Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.

Time frame:
Baseline and after first dose (days 3, 5, 8, 10, 12, 15, and days 17 and 19 for participants dosed on day 22) and after second dose (days 17, 19, and 22 for participants dosed on day 15, and days 24, 26, 29, 32, 36, 43, 50, 64, and 78 in all participants)
Reported as:
Count of participants · Participants
Number of Participants With an Increase in Platelet Count of ≥ 20 x 10⁹ Cells/L From Baseline
ParticipantsRomiplostim 30 µgRomiplostim 100 µgRomiplostim 300 µgRomiplostim 500 µg
After First Dose2451
After Second Dose134—
After Both Doses133—
SecondaryNumber of Participants With Peak Platelet Counts of ≥ 100 x 10⁹ Cells/L

Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.

Time frame:
After first dose (days 3, 5, 8, 10, 12, 15, and days 17 and 19 for participants dosed on day 22), and after second dose (days 17, 19, and 22 for participants dosed on day 15, and days 24, 26, 29, 32, 36, 43, 50, 64, and 78 for all participants)
Reported as:
Count of participants · Participants
Number of Participants With Peak Platelet Counts of ≥ 100 x 10⁹ Cells/L
ParticipantsRomiplostim 30 µgRomiplostim 100 µgRomiplostim 300 µgRomiplostim 500 µg
After First Dose1331
After Second Dose012—
After Both Doses011—
SecondaryNumber of Participants With Peak Platelet Counts of ≥ 450 x 10⁹ Cells/L

Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.

Time frame:
After first dose (days 3, 5, 8, 10, 12, 15, and days 17 and 19 for participants dosed on day 22), and after second dose (days 17, 19, and 22 for participants dosed on day 15, and days 24, 26, 29, 32, 36, 43, 50, 64, and 78 for all participants)
Reported as:
Count of participants · Participants
Number of Participants With Peak Platelet Counts of ≥ 450 x 10⁹ Cells/L
ParticipantsRomiplostim 30 µgRomiplostim 100 µgRomiplostim 300 µgRomiplostim 500 µg
After First Dose0011
After Second Dose000—
After Both Doses000—
SecondaryChange From Baseline to Peak Platelet Level

Platelet count data after the use of rescue medication were not included.

Time frame:
Baseline and after first dose (days 3, 5, 8, 10, 12, 15, and days 17 and 19 for participants dosed on day 22) and after second dose (days 17, 19, and 22 for participants dosed on day 15, and days 24, 26, 29, 32, 36, 43, 50, 64, and 78 in all participants)
Reported as:
Mean · 10⁹ cells/L
Change From Baseline to Peak Platelet Level
10⁹ cells/LRomiplostim 30 µgRomiplostim 100 µgRomiplostim 300 µgRomiplostim 500 µg
After First Dose38.75 ± 50.5089.98 ± 34.44271.3 ± 558.41033.20 ± NA
After Second Dose11.50 ± 14.5146.48 ± 25.1556.38 ± 35.00—
SecondaryTime to Peak Platelet Count

Time from the date of study drug administration (day 1, 15 or 22) to the day of peak platelet count after each dose. Platelet count data after the use of rescue medication were not included.

Time frame:
From first dose of study drug to day 15 or 22, and from the second dose of study drug (day 15 or 22) to day 78
Reported as:
Median · days
Time to Peak Platelet Count
daysRomiplostim 30 µgRomiplostim 100 µgRomiplostim 300 µgRomiplostim 500 µg
After First Dose10.5 (8 to 11)9.0 (5 to 10)12.0 (8 to 13)17.0 (17 to 17)
After Second Dose13.5 (4 to 31)9.5 (8 to 12)9.0 (5 to 15)—
SecondaryDuration Within the Targeted Therapeutic Range

Targeted therapeutic platelet level was defined as a platelet count that was double the baseline level and between 50 and 450 × 10⁹ cells/L. Platelet count data after the use of rescue medication were not included.

Time frame:
From first dose of study drug to day 15 or 22, and from the second dose of study drug (day 15 or 22) to day 78
Reported as:
Median · days
Duration Within the Targeted Therapeutic Range
daysRomiplostim 30 µgRomiplostim 100 µgRomiplostim 300 µgRomiplostim 500 µg
After First Dose10.0 (10 to 10)5.5 (1 to 7)8.0 (5 to 15)—
After Second Dose1.0 (1 to 1)2.0 (2 to 5)8.0 (1 to 49)—

Adverse events

Collected over From first dose through 8 weeks after last dose of study drug (11 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Romiplostim 30 µg—0/4 (0%)4/4 (100%)
Romiplostim 100 µg—0/4 (0%)4/4 (100%)
Romiplostim 300 µg—3/7 (42.9%)7/7 (100%)
Romiplostim 500 µg—1/1 (100%)1/1 (100%)
Most frequent serious events
Most frequent serious events
EventRomiplostim 30 µgRomiplostim 100 µgRomiplostim 300 µgRomiplostim 500 µg
Blood lactate dehydrogenase increasedInvestigations0/40/40/71/1
HeadacheNervous system disorders0/40/40/71/1
AnaemiaBlood and lymphatic system disorders0/40/41/70/1
ThrombocytopeniaBlood and lymphatic system disorders0/40/41/70/1
Rectal haemorrhageGastrointestinal disorders0/40/41/70/1
Lower respiratory tract infectionInfections and infestations0/40/41/70/1
Most frequent other events
Showing 10 of 48
Most frequent other events
EventRomiplostim 30 µgRomiplostim 100 µgRomiplostim 300 µgRomiplostim 500 µg
Back painMusculoskeletal and connective tissue disorders1/40/40/71/1
HeadacheNervous system disorders0/43/44/71/1
HaematomaVascular disorders0/40/41/71/1
PetechiaeVascular disorders0/42/41/71/1
ContusionInjury, poisoning and procedural complications0/42/42/70/1
ArthralgiaMusculoskeletal and connective tissue disorders0/42/43/70/1
FatigueGeneral disorders0/41/43/70/1
Oedema peripheralGeneral disorders0/40/43/70/1
Mouth haemorrhageGastrointestinal disorders0/40/42/70/1
NasopharyngitisInfections and infestations0/41/42/70/1

Baseline characteristics

All enrolled participants

Age, Continuous
Age, Continuous(years)Romiplostim 30 µgRomiplostim 100 µgRomiplostim 300 µgRomiplostim 500 µgTotal
Mean60.3 ± 14.937.8 ± 13.453.9 ± 20.445.050.9 ± 17.9
Sex: Female, Male
Sex: Female, Male(Participants)Romiplostim 30 µgRomiplostim 100 µgRomiplostim 300 µgRomiplostim 500 µgTotal
Female324110
Male12306
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Romiplostim 30 µgRomiplostim 100 µgRomiplostim 300 µgRomiplostim 500 µgTotal
White446115
Black00101
Platelet Count
Platelet Count(10⁹cells/L)Romiplostim 30 µgRomiplostim 100 µgRomiplostim 300 µgRomiplostim 500 µgTotal
Mean13.0 ± 6.1016.5 ± 10.416.4 ± 7.7728.816.3 ± 8.15
09

Study locations

No study locations are listed for this record.

10

References and documents

Publications

  • Cines DB, Wasser J, Rodeghiero F, Chong BH, Steurer M, Provan D, Lyons R, Garcia-Chavez J, Carpenter N, Wang X, Eisen M. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. Haematologica. 2017 Aug;102(8):1342-1351. doi: 10.3324/haematol.2016.161968. Epub 2017 Apr 14. PubMed 28411254 ↗
  • Newland A, Caulier MT, Kappers-Klunne M, Schipperus MR, Lefrere F, Zwaginga JJ, Christal J, Chen CF, Nichol JL. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol. 2006 Nov;135(4):547-53. doi: 10.1111/j.1365-2141.2006.06339.x. PubMed 17061981 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2002 to primary completion in Jul 2004, 19 months.

Results were first posted in Dec 2019, 15 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2005
First posted
Jul 4, 2005
StartActual
Dec 2, 2002
Primary completionActual
Jul 19, 2004
CompletionActual
Jul 19, 2004
Results first posted
Dec 20, 2019
Last update
Jun 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00117143
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jul 4, 2005
Start date
Dec 2, 2002
Primary completion
Jul 19, 2004
Completion
Jul 19, 2004
Results posted
Dec 20, 2019
Last update
Jun 26, 2023

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romiplostim

Start the discussion